Related Experiment Video

Updated: Jul 13, 2026

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Levetiracetam in nonconvulsive status epilepticus in childhood: a case report

Antonio Trabacca1, Paolo Profice, Maria Carmela Costanza

  • 1Scientific Institute Eugenio Medea, Association La Nostra Famiglia, OSTUNI (Brindisi), Department of Neurorehabilitation I, Developmental Neurology and Functional Rehabilitation, Ostuni, Italy. antonio.trabacca@os.lnf.it

Journal of Child Neurology
|August 11, 2007
PubMed

Insights

Levetiracetam effectively treated nonconvulsive status epilepticus in a child with cerebral palsy and epilepsy. This conservative approach offers a promising treatment option for pediatric nonconvulsive status epilepticus.

Area of Science:

  • Pediatric Neurology
  • Epileptology
  • Clinical Case Study

Background:

  • Cerebral palsy and refractory epilepsy can predispose children to nonconvulsive status epilepticus.
  • Treatment of nonconvulsive status epilepticus (NCSE) often requires careful consideration of patient-specific factors.
  • Aggressive treatment strategies may negatively impact prognosis in certain patient populations.

Observation:

  • A pediatric patient with cerebral palsy and refractory epilepsy developed nonconvulsive status epilepticus.
  • The patient's condition was managed with a conservative treatment approach.
  • Levetiracetam was administered as the primary therapeutic agent.

Findings:

  • Successful resolution of nonconvulsive status epilepticus was achieved with levetiracetam.
  • The conservative management strategy proved effective in this pediatric case.
  • Levetiracetam demonstrated efficacy in treating NCSE without an acute medical cause.

Implications:

  • Levetiracetam represents a viable and effective treatment option for childhood nonconvulsive status epilepticus.
  • This case supports the use of levetiracetam in pediatric epilepsy management, aligning with prior research.
  • Conservative treatment approaches may be beneficial for NCSE in specific pediatric populations.

More Related Videos

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Seizures l: Introduction01:20

Seizures l: Introduction

Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...